Recommended Topic Related To:

Kyprolis

"The U.S. Food and Drug Administration today approved Cyramza (ramucirumab) to treat patients with advanced stomach cancer or gastroesophageal junction adenocarcinoma, a form of cancer located in the region where the esophagus joins the stomach./"...

Kyprolis

Kyprolis Side Effects Center

Medical Editor: John P. Cunha, DO, FACOEP

Kyprolis (carfilzomib) is indicated to treat patients with multiple myeloma who have received at least two prior therapies, including treatment with Velcade (bortezomib) and an immunomodulatory therapy. The most common side effects are fatigue, low blood cell count and blood platelet levels, shortness of breath, diarrhea, and fever. Serious side effects included heart failure and shortness of breath. Patients should be monitored closely and treatment withheld if these serious side effects occur.

Kyprolis is administered intravenously over 2 to 10 minutes, on two consecutive days each week for three weeks, followed by a 12-day rest period. The recommended cycle 1 dose is 20 mg/m2/day and if tolerated increase cycle 2 dose and subsequent cycles doses to 27 mg/m2/day. Other drugs may interact with Kyprolis. Tell your doctor all medications you use. Kyprolis can cause fetal harm. Women should avoid becoming pregnant while being treated. Female patients should be advised that if she becomes pregnant during treatment, to contact her physician immediately. Advise patients not to take Kyprolis treatment while pregnant or breastfeeding. If a patient wishes to restart breastfeeding after treatment, advise her to discuss the appropriate timing with her physician.

Our Kyprolis Side Effects Drug Center provides a comprehensive view of available drug information on the potential side effects when taking this medication.

This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

What is Prescribing information?

The FDA package insert formatted in easy-to-find categories for health professionals and clinicians.

Kyprolis FDA Prescribing Information: Side Effects
(Adverse Reactions)

SIDE EFFECTS

The following adverse reactions are discussed in greater detail in other sections of the labeling:

The most common adverse reactions (incidence of 30% or greater) to KYPROLIS observed in clinical trials of patients with multiple myeloma were fatigue, anemia, nausea, thrombocytopenia, dyspnea, diarrhea, and pyrexia.

Clinical Trials Safety Experience

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared with rates in the clinical trials of another drug, and may not reflect the rates observed in medical practice.

A total of 526 patients with relapsed and/or refractory multiple myeloma received KYPROLIS as monotherapy or with pre-dose dexamethasone. Patients received a median of four treatment cycles with a median cumulative KYPROLIS dose of 993.4 mg.

Deaths due to all causes within 30 days of the last dose of KYPROLIS occurred in 37/526 (7%) of patients. Deaths not attributed to disease progression were cardiac in 5 patients (acute coronary syndrome, cardiac arrest, cardiac disorder), end-organ failure in 4 patients (multi-organ failure, hepatic failure, renal failure), infection in 4 patients (sepsis, pneumonia, respiratory tract bacterial infection), dyspnea and intracranial hemorrhage in 1 patient each, and 1 patient found dead of unknown causes.

Serious adverse reactions were reported in 45% patients. The most common serious adverse reactions were pneumonia (10%), acute renal failure (4%), pyrexia (3%), and congestive heart failure (3%). Adverse reactions leading to discontinuation of KYPROLIS occurred in 15% of patients and included congestive heart failure (2%), cardiac arrest, dyspnea, increased blood creatinine, and acute renal failure (1% each).

Adverse reactions occurring at a rate of 10% or greater are presented in Table 4.

Table 4: Incidence of Adverse Reactions Occurring in ≥ 10% of Multiple Myeloma Patients Treated with KYPROLIS

Event Patients (N = 526) [n (%)]
All Gradesa Grade 3 Events Grade 4 Events
Fatigue 292 (55.5) 38 (7.2) 2 (0.4)
Anemia 246 (46.8) 111 (21.1) 7 (1.3)
Nausea 236 (44.9) 7 (1.3) 0
Thrombocytopenia 191 (36.3) 69 (13.1) 54 (10.3)
Dyspnea 182 (34.6) 25 (4.8) 1 (0.2)b
Diarrhea 172 (32.7) 4 (0.8) 1 (0.2)
Pyrexia 160 (30.4) 7 (1.3) 2 (0.4)
Upper respiratory tract infection 149 (28.3) 17 (3.2) 0
Headache 145 (27.6) 7 (1.3) 0
Cough 137 (26.0) 1 (0.2) 0
Blood creatinine increased 127 (24.1) 13 (2.5) 1 (0.2)
Lymphopenia 126 (24.0) 84 (16.0) 11 (2.1)
Edema peripheral 126 (24.0) 3 (0.6) 0
Vomiting 117 (22.2) 5 (1.0) 0
Constipation 110 (20.9) 1 (0.2) 0
Neutropenia 109 (20.7) 50 (9.5) 4 (0.8)
Back pain 106 (20.2) 15 (2.9) 0
Insomnia 94 (17.9) 0 0
Chills 84 (16.0) 1 (0.2) 0
Arthralgia 83 (15.8) 7 (1.3) 0
Muscle spasms 76 (14.4) 2 (0.4) 0
Hypertension 75 (14.3) 15 (2.9) 2 (0.4)
Asthenia 73 (13.9) 12 (2.3) 1 (0.2)
Hypokalemia 72 (13.7) 14 (2.7) 3 (0.6)
Hypomagnesemia 71 (13.5) 2 (0.4) 0
Leukopenia 71 (13.5) 27 (5.1) 1 (0.2)
Pain in extremity 70 (13.3) 7 (1.3) 0
Pneumonia 67 (12.7) 52 (9.9) 3 (0.6)b
Aspartate aminotransferase increased 66 (12.5) 15 (2.9) 1 (0.2)
Dizziness 66 (12.5) 5 (1.0) 1 (0.2)
Hypoesthesia 64 (12.2) 3 (0.6) 0
Anorexia 63 (12.0) 1 (0.2) 0
Pain 63 (12.0) 12 (2.3) 1 (0.2)
Hyperglycemia 62 (11.8) 16 (3.0) 3 (0.6)
Chest wall pain 60 (11.4) 3 (0.6) 0
Hypercalcemia 58 (11.0) 13 (2.5) 8 (1.5)
Hypophosphatemia 55 (10.5) 24 (4.6) 3 (0.6)
Hyponatremia 54 (10.3) 31 (5.9) 3 (0.6)
aNational Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version 3.0
bOne event was Grade 5 severity.

Description of Selected Adverse Drug Reactions

Renal Events

The most common renal adverse reactions were increase in blood creatinine (24%) and renal failure (9%), which were mostly Grade 1 or Grade 2 in severity. Grade 3 renal adverse reactions occurred in 6% of patients and Grade 4 events occurred in 1%. Discontinuations due to increased blood creatinine and acute renal failure were 1% each. In one patient, death occurred with concurrent sepsis and worsening renal function [see DOSAGE AND ADMINISTRATION].

Peripheral Neuropathy

Peripheral neuropathy (including all events of peripheral sensory neuropathy and peripheral motor neuropathy) occurred in 14% of patients enrolled in clinical trials. Grade 3 peripheral neuropathy occurred in 1% of patients. Serious peripheral neuropathy events occurred in < 1% of patients, which resulted in dose reduction in < 1% and treatment discontinuation in < 1%. Withhold or discontinue treatment as recommended [see DOSAGE AND ADMINISTRATION].

Herpes Virus Infection

Herpes zoster reactivation was reported in 2% of patients. Consider antiviral prophylaxis for patients who have a history of herpes zoster infection.

Read the entire FDA prescribing information for Kyprolis (Carfilzomib) »

A A A

Report Problems to the Food and Drug Administration

 

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.


Cancer

Get the latest treatment options.